Tarun Chandra, CFA
Contributor since: 2008
Company: Graycell advisors and prudent biotech
The Trade War Has An Upside
Sell Or Hold As Volatility Strikes
Biotechs' Second-Half Battle
Biotech Stocks Getting Ready To Explode
A Biotech Friendly Event In An Unfriendly Healthcare Market
3 Gene Therapy Stocks For A Biotech Portfolio
Market At New Highs, But Healthcare And Biotechs Feel The Heat
Zero Spread Is Not Stomping Out A Bull Market Yet
Biotech M&A Theme Builds Momentum
Biotech Bonanza: The Mergers And Acquisitions Theme
Does The Bull Survive? Stock Market Outlook 2019
So We Got Ourselves A Bear. Now Let's Go Find A Recession.
Biotech Bonanza: 2019 Outlook On An Uphill Battle
A Migrating Biotech Bear
This Stock Reset Requires Patience
Biotech Stocks Bloodied But Can Now Drive M&A
A Federal Reserve Jolt
The Biotech Conundrum
An Upheaval: Systematic Thinkers Toll The Bell
Small Caps Are Rising, Biotechs Can't Be Far Behind
Biotech Stocks Are Tariff-Safe And Building Momentum
Second Half Outlook: What Now After Strong Double-Digit Gains?
A Short Case For A Longer Term!
ASCO Delivers A Biotech Boost, As The Market Waits On Trump-Kim And The Fed
Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher
Small Caps Charge, Augurs Well For The Stock Market
Biotechs Emerge Unscathed And Ready To Go!
Small Caps: The Bright Spot In A Challenging Stock Market
Biotechs, Whipsawed By Volatility, Still Remain Well-Positioned
Biotechs Approaching New Waters
Stock Market: It's Not Over Yet
Biotechs: Still Well Placed For More Gains